English
Back
Open Account
SINOHEALTH HLDG
wrote a post · Jul 1 14:16

Zhongkang Technology officially launched its AI agent product 'Deep Pharma'—an AI-powered intelligence research team designed to support new drug project initiation and business development (BD) decision-making

$SINOHEALTH TECH (02361.HK)$
Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically designed for pharmaceutical R&D, business development (BD), and industrial investment teams. This marks Zhongkang’s expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, leveraging AI capabilities to empower decision-making across the full spectrum from drug discovery to commercialization.
Deep Pharma’s five core capabilities cover all scenarios in R&D decision-making
I. Competitive Landscape Analysis
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
Based on the user’s specific area of interest (e.g., disease, target, drug type), Deep Pharma evaluates from multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis.
Compared with the single-function search capability of traditional databases,Deep Pharmais built upon amulti-agent collaborative architectureto automatically completeData Collection → Evidence Chain Verification → In-depth Analysis → Delivery-Ready Report GenerationThe end-to-end process clearly maps global project portfolios, R&D stages, and latest developments across vendors, enabling rapid mastery of the competitive landscape.
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
II. Zhongkang’s Robust Data Foundation Built Over 19 Years
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
Deep Pharma is built upon Zhongkang’s solid data foundation, covering globally70,000+ active novel drug pipelines、18,000+ target data points、700,000+ clinical trial recordsand40 million+ literature and conference data entriesThis deep repository spans the entire drug lifecycle from Discovery to commercialization. Zhongkang’s core pharmaceutical market sales data assets will soon be integrated to support drug portfolio planning and BD assessments of market size—stay tuned.
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
III. Expert-Level AI Team Deep Research Reports
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
Multi-Agent AI TeamCollaborative Workflow:AI Project ManagerReceives requirements, interprets intent, and formulates task plans;AI Analyst TeamConcurrently invokes retrieval tools to systematically gather and synthesize data;Business AnalystTranslates analytical findings into actionable business insights tailored to specific scenarios;Review ExpertPerforms logical validation and key-point review of every conclusion, verifying each cited source item by item to ensure full traceability of all data. The resulting report meets the pharmaceutical industry’s stringent accuracy standards and rivals the quality produced by professional consulting teams.
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
4. End-to-End Zero Hallucination Mechanism
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
A rigorous citation and source-tracing mechanism ensures all conclusions are based on credible sources, accompanied by original text links and screenshots, meeting the stringent accuracy requirements of the pharmaceutical and healthcare industries. Every data point and conclusion can be precisely traced back to its source, eliminating the risk of AI hallucinations.
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
5. Enterprise-Grade Data Security Protection
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
Zhongkang Technology has obtained Level 3 certification under China’s Information System Security Classification Protection scheme and holdsISO 9000、ISO 20000、ISO 27001、ISO 27701four international management system certifications, and its R&D processes comply withCMMI DEV Maturity Level 3Requirement: comprehensive protection of customer data asset security.
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
Zhongkang Technology serves over 2,000 pharmaceutical companies and has long accompanied clients through their growth journey.
Deep Pharma is independently developed by Zhongkang Technology. The company has deep expertise in the pharmaceutical and healthcare industry, having cumulatively served more than 2,000 brand-name pharmaceutical and innovative drug companies. It has long supported domestic innovative drug firms throughout their entire decision-making cycle—from project initiation to market launch—and established long-term collaborations with leading global multinational pharmaceutical companies. Leveraging its deep accumulation in industry data and AI capabilities, Deep Pharma will provide smarter, more traceable professional support for drug R&D and business development (BD) decision-making.
$SINOHEALTH TECH (02361.HK)$ Recently, Zhongkang Technology officially launched its AI agent product Deep Pharma —an AI agent product specifically built for pharmaceutical R&D, business development (BD), and industrial investment teams, marking Zhongkang's strategic expansion from digital and intelligent commercialization services for pharmaceuticals into the entire new drug R&D value chain, empowering end-to-end decision-making from drug discovery to commercialization with AI capabilities. Deep Pharma’s five core capabilities cover all scenarios of R&D decision-making I. Competitive Landscape Analysis Based on the user’s specific area of interest (e.g., disease, target, drug type, etc.), Deep Pharma evaluates across multiple dimensions—including mechanism of action, existing therapies, competitive landscape, clinical efficacy, safety, and patient adherence—and delivers expert-level SWOT analysis. Compared with the single-search functionality of traditional databases,Deep Pharmais based on multi-Intelligent Agent Collaboration Architecture, automatically completingthe entire workflow from data collection → evidence chain verification → in-depth analysis → delivery-grade report generation, clearly presenting global project pipelines, R&D stages, and latest developments across vendors to quickly grasp the full landscape of the sector. II. Zhongkang’s robust data foundation built over 19 years Deep Pharma is built upon Zhongkang’s solid underlying data infrastructure, covering globallyover 70,000 active new drug pipelines,、over 18,000 target data points,、over 700,000 clinical trial records,andover 40 million+...
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
1464 Views
Report
Comments
Write a Comment...